Brussels, 11 November 2022
The Commission granted a marketing authorisation as a booster dose for VidPrevtyn Beta, the protein-based COVID19 vaccine developed by Sanofi and GSK, and the seventh COVID-19 vaccine authorised in the EU. This authorisation covers the use of the vaccine as a booster dose for adults following primary vaccination with another COVID-19 vaccine. The authorisation follows a positive scientific recommendation from the European Medicines Agency (EMA) based on a thorough assessment of the safety, effectiveness, and quality of the vaccine, and is endorsed by the Member States. Having diversity and options in the vaccines against COVID-19 is essential to ensure citizens are well protected. The Commission and Member States negotiated an Advance Purchase Agreement with Sanofi and GSK which entered into force on 18 September 2020, which gives the EU Member States the option to purchase up to 300 million doses of the vaccine if they wish to. Member States may also use these vaccines to donate vaccines to low-and middle-income countries. The EU portfolio now contains seven safe and effective COVID-19 vaccines. For more information on the vaccine portfolio, please consult this page.
Source – EU Commission